Thermo Fisher Scientific Announces Inaugural 2015 Attune NxT Flow Cytometry Grant
Dr Charles Prussak will receive the grant to help further his research on immune-cell therapy for cancer treatment
8 Dec 2015
Life sciences company Thermo Fisher Scientific is awarding Charles Prussak, Pharm D, PhD, and Director of the Cell Therapy Translational Laboratory at The University of California, San Diego, the inaugural 2015 Attune NxT Flow Cytometry Grant. Dr. Prussak will receive a 4-laser Invitrogen™ Attune™ NxT Flow Cytometer, which is a revolutionary benchtop analyzer that aligns cells prior to interrogation with a laser for multicolor flow cytometry, to help further his research on immune-cell therapy for cancer treatment.
The Attune NxT Flow Cytometry Grant was launched in March 2015 with an open call for proposals among organizations pursuing innovative research that advance scientific understanding through the use of flow cytometry. With more than 200 submissions from 40 states and 20 countries, the judging panel selected Dr. Prussak as the North American winner based on the significance, approach, creativity and feasibility of his submission, which explained how Thermo Fisher’s Attune flow cytometer’s novel acoustic focusing technology would further the goals of his cancer research, while also having an impact within the life science research community.
A second grant was awarded to Dr. Bruno Sainz of the Universidad Autónoma de Madrid in Madrid, Spain, who holds the prestigious Ramon and Cajal Investigator title, for his submission on the development of a state-of-the art liquid biopsy assay for detection of circulating cancer stem cells fused to macrophages in human blood.
Dr. Prussak will be honored at a ceremony at Thermo Fisher Scientific in Carlsbad on December 10.
